Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To estimate objective response rate (ORR) of dasatinib in women with recurrent or progressive locally-advanced or metastatic 'triple-negative' breast cancer.
Critère d'inclusion
- Recurrent or progressive locally-advanced or metastatic 'triple-negative' breast cancer